BiotechTube
Home/Pipeline/Liquid Biopsy for HER2 Status

Liquid Biopsy for HER2 Status

Breast Cancer

Assay Development/ValidationActive

Key Facts

Indication
Breast Cancer
Phase
Assay Development/Validation
Status
Active
Company
Wobble Genomics

About Wobble Genomics

Wobble Genomics is an early-stage biotech (founded 2020) pioneering a liquid biopsy platform based on full-length, long-read RNA sequencing. Its core technologies, Level-Up (biochemical) and TAMA (bioinformatics), are designed to unlock and analyze low-abundance RNA from blood, revealing novel biomarkers for cancer. The company has presented early validation data at major conferences (SABCS 2025, ESMO 2025), demonstrating application in breast cancer (HER2 profiling) and platform robustness. It operates as a private, pre-revenue diagnostics platform company targeting a significant opportunity in non-invasive cancer testing.

View full company profile

Therapeutic Areas

Oncology

Other Breast Cancer Drugs

DrugCompanyPhase
Antifibrotic Therapy ProgramMeCo DiagnosticsPre-clinical
inPROBE for HER2SDS OpticClinical Investigation
ACT‑BC1AnthrocellPreclinical
APA-1000 Breast Thermotherapy SystemMedifocusPhase III
Early‑Detection Breast Cancer ScreeningKarkinos HealthcareMarket
Unnamed Breast Cancer ProgramClick TherapeuticsPilot/Phase 2
Lerociclib (Lerocliclib)Chemogenics BioPharmaPhase 3
AT-017Asieris PharmaceuticalsNot Specified
CDK2 inhibitorAcelleraPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
Maveropepimut-S (MVP-S)BioVaxysClinical Evaluation
Cannabics® BRST-33CNBX PharmaceuticalsDiscovery